Navigation auf zora.uzh.ch

Search ZORA

ZORA (Zurich Open Repository and Archive)

Prognostic value of O-(2-[$^{18}$F]-fluoroethyl)-L-tyrosine PET in relapsing oligodendroglioma

Schneider, Florian; Wolpert, Fabian; Stolzmann, Paul; Albatly, Abdulrahman A; Kenkel, David; Weller, Jonathan; Weller, Michael; Kollias, Spyros S; Rushing, Elisabeth J; Veit-Haibach, Patrick; Huellner, Martin W (2020). Prognostic value of O-(2-[$^{18}$F]-fluoroethyl)-L-tyrosine PET in relapsing oligodendroglioma. Acta Oncologica, 59(11):1357-1364.

Abstract

PURPOSE

To assess the relationship between F-18-fluoro-ethyl-tyrosine positron emission tomography (FET-PET) parameters of relapsing oligodendroglioma and progression-free survival.

MATERIAL AND METHODS

The relationship of clinical parameters, FET-PET parameters (SUV$_{max}$, TBR$_{max}$, BTV$_{,}$ time-activity curves) and progression-free survival was analyzed using univariate and multivariate analysis in 42 adult patients with relapsing oligodendroglioma. Kaplan-Meier analysis was used to assess survival.

RESULTS

Patients who did not undergo surgical resection of their relapsing tumor had significantly lower PFS if the tumor exhibited an SUV$_{max}$ above 3.40 than those with an SUV$_{max}$ below 3.40 (13.1 ± 2.3 months vs. 47.3 ± 6.0 months, respectively, p < .001). Patients who underwent surgery had similar PFS as the aforementioned non-operated patients with low SUV$_{max}$ (53.6 ± 6.7 months, p = .948). The same was true for TBR$_{max}$ using a threshold of 3.03 (PFS 12.5 ± 2.4 months vs. 44.0 ± 6.3 months / 53.6 ± 6.7 months, respectively; p < .001 / p = .825). Also, subjects with BTV below 10 cm$^{3}$ that did not undergo surgery had a similar PFS as subjects who underwent surgery (40.2 ± 6.0 months vs. 52.4 ± 8.9 months, respectively, p = .587). Subjects with BTV above 10 cm$^{3}$ and without surgery had a significantly worse PFS (13.8 ± 3.3 months, p < .001). Multivariate analysis showed that the prognostication by clinical parameters is improved by adding TBR$_{max}$ to the model (AUC 0.945 (95% CI: 0.881-1.000), true classification rate 88.1%).

CONCLUSION

FET-PET may provide added value for the prognostication of relapsing oligodendroglioma in addition to clinical parameters.

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
04 Faculty of Medicine > University Hospital Zurich > Clinic for Neuroradiology
04 Faculty of Medicine > University Hospital Zurich > Clinic for Nuclear Medicine
04 Faculty of Medicine > University Hospital Zurich > Institute of Neuropathology
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Health Sciences > Hematology
Health Sciences > Oncology
Health Sciences > Radiology, Nuclear Medicine and Imaging
Language:English
Date:1 November 2020
Deposited On:07 Aug 2020 09:13
Last Modified:23 Dec 2024 02:38
Publisher:Informa Healthcare
ISSN:0284-186X
OA Status:Closed
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1080/0284186X.2020.1787507
PubMed ID:32686979

Metadata Export

Statistics

Citations

Dimensions.ai Metrics
2 citations in Web of Science®
2 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

2 downloads since deposited on 07 Aug 2020
0 downloads since 12 months
Detailed statistics

Authors, Affiliations, Collaborations

Similar Publications